Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma

Allison Zwingenberger, Michael S Kent, Changying Shi, Sandra L. Taylor, Xiucui Chen, Kit Lam

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Lymphoma is an important disease in dogs and people, with similar biological characteristics. We tested the binding affinity of a peptidomimetic LLP2A, previously shown to bind the alpha4-beta1 integrin on human lymphoma cell lines, to lymphocytes of dogs with spontaneously occurring lymphoma. Fine needle aspirates of lymph nodes from 32 dogs with B-cell lymphoma and 7 dogs with T-cell lymphoma were evaluated using flow cytometry. For B cells, the lowest MFI levels were in unlabeled, non-neoplastic lymphocytes. The highest median fluorescent intensity (MFI) levels occurred in LLP2A-labeled lymphoma cells from dogs that had not received chemotherapy followed by labeled lymphoma cells from dogs that had received chemotherapy. The fluorescence profile of the T-cell samples was similar although many of the differences were not statistically significant, likely due to low sample number. Specifically, LLP2A-labeled T-cell lymphoma cells had a significantly higher MFI compared to unlabeled non-neoplastic lymphocytes. LLP2A affinity was not significantly different in unlabeled and labeled T-cell lymphoma cells, and labeled non-neoplastic lymphocytes. For both B and T cells, labeling with LLP2A tended to increase MFI in both normal and lymphoma cells. Lymphoma cells had higher mean MFI levels than non-neoplastic lymphocytes, and chemotherapy acted to decrease MFI. In summary, these data demonstrate that LLP2A has affinity to canine lymphoma cells and indicates expression of the alpha4-beta1 integrin on these cells. In fact, LLP2A preferentially binds neoplastic B-cells, suggesting that this small molecule may be of use in cross-species clinical trials of targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)298-304
Number of pages7
JournalVeterinary Immunology and Immunopathology
Volume145
Issue number1-2
DOIs
StatePublished - Jan 15 2012

Fingerprint

CD29 Antigens
lymphoma
Canidae
Lymphoma
peptides
Peptides
dogs
Dogs
Lymphocytes
T-Cell Lymphoma
lymphocytes
T-lymphocytes
B-lymphocytes
B-Lymphocytes
Drug Therapy
cells
drug therapy
Dog Diseases
Peptidomimetics
T-Lymphocytes

Keywords

  • Canine
  • LLP2A
  • Lymphoma
  • Non-Hodgkin's
  • Peptidomimetic

ASJC Scopus subject areas

  • Immunology
  • veterinary(all)

Cite this

Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma. / Zwingenberger, Allison; Kent, Michael S; Shi, Changying; Taylor, Sandra L.; Chen, Xiucui; Lam, Kit.

In: Veterinary Immunology and Immunopathology, Vol. 145, No. 1-2, 15.01.2012, p. 298-304.

Research output: Contribution to journalArticle

@article{27f55b4973814c1e953cde7fae12870b,
title = "Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma",
abstract = "Lymphoma is an important disease in dogs and people, with similar biological characteristics. We tested the binding affinity of a peptidomimetic LLP2A, previously shown to bind the alpha4-beta1 integrin on human lymphoma cell lines, to lymphocytes of dogs with spontaneously occurring lymphoma. Fine needle aspirates of lymph nodes from 32 dogs with B-cell lymphoma and 7 dogs with T-cell lymphoma were evaluated using flow cytometry. For B cells, the lowest MFI levels were in unlabeled, non-neoplastic lymphocytes. The highest median fluorescent intensity (MFI) levels occurred in LLP2A-labeled lymphoma cells from dogs that had not received chemotherapy followed by labeled lymphoma cells from dogs that had received chemotherapy. The fluorescence profile of the T-cell samples was similar although many of the differences were not statistically significant, likely due to low sample number. Specifically, LLP2A-labeled T-cell lymphoma cells had a significantly higher MFI compared to unlabeled non-neoplastic lymphocytes. LLP2A affinity was not significantly different in unlabeled and labeled T-cell lymphoma cells, and labeled non-neoplastic lymphocytes. For both B and T cells, labeling with LLP2A tended to increase MFI in both normal and lymphoma cells. Lymphoma cells had higher mean MFI levels than non-neoplastic lymphocytes, and chemotherapy acted to decrease MFI. In summary, these data demonstrate that LLP2A has affinity to canine lymphoma cells and indicates expression of the alpha4-beta1 integrin on these cells. In fact, LLP2A preferentially binds neoplastic B-cells, suggesting that this small molecule may be of use in cross-species clinical trials of targeted therapeutics.",
keywords = "Canine, LLP2A, Lymphoma, Non-Hodgkin's, Peptidomimetic",
author = "Allison Zwingenberger and Kent, {Michael S} and Changying Shi and Taylor, {Sandra L.} and Xiucui Chen and Kit Lam",
year = "2012",
month = "1",
day = "15",
doi = "10.1016/j.vetimm.2011.11.018",
language = "English (US)",
volume = "145",
pages = "298--304",
journal = "Veterinary Immunology and Immunopathology",
issn = "0165-2427",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma

AU - Zwingenberger, Allison

AU - Kent, Michael S

AU - Shi, Changying

AU - Taylor, Sandra L.

AU - Chen, Xiucui

AU - Lam, Kit

PY - 2012/1/15

Y1 - 2012/1/15

N2 - Lymphoma is an important disease in dogs and people, with similar biological characteristics. We tested the binding affinity of a peptidomimetic LLP2A, previously shown to bind the alpha4-beta1 integrin on human lymphoma cell lines, to lymphocytes of dogs with spontaneously occurring lymphoma. Fine needle aspirates of lymph nodes from 32 dogs with B-cell lymphoma and 7 dogs with T-cell lymphoma were evaluated using flow cytometry. For B cells, the lowest MFI levels were in unlabeled, non-neoplastic lymphocytes. The highest median fluorescent intensity (MFI) levels occurred in LLP2A-labeled lymphoma cells from dogs that had not received chemotherapy followed by labeled lymphoma cells from dogs that had received chemotherapy. The fluorescence profile of the T-cell samples was similar although many of the differences were not statistically significant, likely due to low sample number. Specifically, LLP2A-labeled T-cell lymphoma cells had a significantly higher MFI compared to unlabeled non-neoplastic lymphocytes. LLP2A affinity was not significantly different in unlabeled and labeled T-cell lymphoma cells, and labeled non-neoplastic lymphocytes. For both B and T cells, labeling with LLP2A tended to increase MFI in both normal and lymphoma cells. Lymphoma cells had higher mean MFI levels than non-neoplastic lymphocytes, and chemotherapy acted to decrease MFI. In summary, these data demonstrate that LLP2A has affinity to canine lymphoma cells and indicates expression of the alpha4-beta1 integrin on these cells. In fact, LLP2A preferentially binds neoplastic B-cells, suggesting that this small molecule may be of use in cross-species clinical trials of targeted therapeutics.

AB - Lymphoma is an important disease in dogs and people, with similar biological characteristics. We tested the binding affinity of a peptidomimetic LLP2A, previously shown to bind the alpha4-beta1 integrin on human lymphoma cell lines, to lymphocytes of dogs with spontaneously occurring lymphoma. Fine needle aspirates of lymph nodes from 32 dogs with B-cell lymphoma and 7 dogs with T-cell lymphoma were evaluated using flow cytometry. For B cells, the lowest MFI levels were in unlabeled, non-neoplastic lymphocytes. The highest median fluorescent intensity (MFI) levels occurred in LLP2A-labeled lymphoma cells from dogs that had not received chemotherapy followed by labeled lymphoma cells from dogs that had received chemotherapy. The fluorescence profile of the T-cell samples was similar although many of the differences were not statistically significant, likely due to low sample number. Specifically, LLP2A-labeled T-cell lymphoma cells had a significantly higher MFI compared to unlabeled non-neoplastic lymphocytes. LLP2A affinity was not significantly different in unlabeled and labeled T-cell lymphoma cells, and labeled non-neoplastic lymphocytes. For both B and T cells, labeling with LLP2A tended to increase MFI in both normal and lymphoma cells. Lymphoma cells had higher mean MFI levels than non-neoplastic lymphocytes, and chemotherapy acted to decrease MFI. In summary, these data demonstrate that LLP2A has affinity to canine lymphoma cells and indicates expression of the alpha4-beta1 integrin on these cells. In fact, LLP2A preferentially binds neoplastic B-cells, suggesting that this small molecule may be of use in cross-species clinical trials of targeted therapeutics.

KW - Canine

KW - LLP2A

KW - Lymphoma

KW - Non-Hodgkin's

KW - Peptidomimetic

UR - http://www.scopus.com/inward/record.url?scp=84856543584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856543584&partnerID=8YFLogxK

U2 - 10.1016/j.vetimm.2011.11.018

DO - 10.1016/j.vetimm.2011.11.018

M3 - Article

VL - 145

SP - 298

EP - 304

JO - Veterinary Immunology and Immunopathology

JF - Veterinary Immunology and Immunopathology

SN - 0165-2427

IS - 1-2

ER -